Hot Pursuit
Prev Next
As on Dec 15, 2017 12:00 AM Your results on : Hot Pursuit    
AstraZeneca gains as company to launch diabetes drug
15-Dec-2017 (15:13)
The announcement was made after market hours yesterday, 14 December 2017.

Meanwhile, the S&P BSE Sensex was up 276.83 points, or 0.83% to 33,523.53. The S&P BSE Small-Cap index was up 247.49 points, or 1.38% to 18,170.94.

On the BSE, 1,617 shares were traded in the counter so far, compared with average daily volumes of 6,261 shares in the past one quarter. The stock had hit a high of Rs 1,163.45 and a low of Rs 1,131 so far during the day. The stock had hit a 52-week high of Rs 1,278 on 7 November 2017. The stock had hit a 52-week low of Rs 882.55 on 22 August 2017.

The stock lost 4.5% over the past one month till 14 December 2017, underperforming the Sensex's 0.93% rise. The scrip however, outperformed the market in past one quarter, gaining 15.73% as against Sensex's 3.12% rise. The scrip, however, underperformed the market in past one year, advancing 18.43% as against Sensex's 24.97% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma India said that subject to the receipt of Import License from the Drugs Controller General of India, the FDC of Dapagliflozin + Metformin Hydrochloride film coated tablets (XIGDUO XR) is expected to be launched in India in Q4 of FY 2017-18.

XIGDUO XR is a product of AstraZeneca Group and has been approved in 61 countries to date including US, EU and Japan. XIGDUO XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Dapaglifiozin and Metformin is appropriate.

Astrazeneca Pharma India's net profit rose 3322.5% to Rs 27.38 crore on 18.9% rise in net sales to Rs 164.26 crore in Q2 September 2017 over Q2 September 2016.

AstraZeneca Pharma India is a subsidiary of AstraZeneca Plc, UK. It covers manufacturing, sales and marketing activities of the company in India. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular and & metabolic diseases, oncology and respiratory.

GMR Infra heads north after consortium wins airport project
15-Dec-2017 (14:33)
HCL Infosystems leads gainers in 'A' group
15-Dec-2017 (14:16)
Eveready Industries electrifies after winning orders
15-Dec-2017 (14:10)
Volumes jump at Techno Electric & Engineering Company counter
15-Dec-2017 (13:42)
Goodluck India shines after good Q2 result
15-Dec-2017 (12:52)
Renaissance Jewellery hits the roof after stellar Q2 outcome
15-Dec-2017 (12:24)
Royal Orchid Hotels in spotlight after opening new hotel
15-Dec-2017 (12:18)
Shalby sees dull debut on bourses
15-Dec-2017 (11:40)
Gufic Biosciences scales record high after posting robust Q2 results
15-Dec-2017 (11:30)
Linc Pen & Plastics drops after dismal Q2 outcome
15-Dec-2017 (10:57)
Gulf Oil glitters after starting lubricant oil production at plant
15-Dec-2017 (10:51)
Vedanta shines on fund raising plan
15-Dec-2017 (10:20)
M&M revs up after announcing price hike
15-Dec-2017 (09:57)
HDFC Bank scales record high on fund raising plan
15-Dec-2017 (09:40)
Natco Pharma spurts as committee approves closure of QIP
14-Dec-2017 (15:23)
Ruchi Soya slumps as IDBI Bank declares it defaulter
14-Dec-2017 (14:41)
Corporation Bank drops after RBI keeps it under prompt corrective action
14-Dec-2017 (14:40)
Lupin in pink of health after USFDA nod for contraceptive tablets
14-Dec-2017 (14:13)
SMS Pharmaceuticals drops after tiny growth in PAT in Q2
14-Dec-2017 (13:44)
Connect with us :   
About us
Our Services
Core Values
Investor Relations
Product & Services
Institutional Broking
Clearing Services
Trade & Products
Globe Connect Pro
Globe Trade Smart
Globe Connect Mobile/Tablet
Globe News Connect
Globe e-KYC Application
Back Office
Back Office
KYC/KDC Status
Mutual Fund
RMS Policy
Download Forms
Useful Links
Exchange Holidays
Policies, Procedures, Rights, Obligations and RDD
Guidance Note on FATCA and CRS May 2016
Right and Obligation, RDD, Guidance Note in Vernacular Language - Equity | Commodity
Additional Risk Disclosure for Trading into Commodity options
In case of any grievances pleae write to / (For Trading) (For DP) (For PMS) (For Commodities)
SEBI Regn. No. NSE.:INB/INF/INE 230663732, TM No.:06637, Clearing No.- M50302 | SEBI Regn. No. BSE.:INB/INF/INE 010663731, Clearing No.- 3179 | SEBI Regn No. MSEI :INB/F 260663738, INE 260663732, TM Code-1004, Clearing Member Code- 4 | SEBI Regn for DP : IN-DP-NSDL-97-99, NSDL- DP ID: IN300966, CDSL DP ID: 12020600 | Research Analysts Regn No. INH100001187 | PMS Regn No. INP000002361
* Through subsidiary Globe Commodities Ltd. --> Commodity SEBI Regn. No. - INZ000024939, Exchange Regn. Nos. - MCX CM ID: 8550 TM ID: 10735, NCDEX CM ID: M50011 TM ID: 00012, NMCE ID: CL0111, ICEX ID: 1009, NCDXSPOT-CR-07-10011,
** Through step in subsidiary Globe Comex International DMCC --> DGCX **TM Id.1064, CM Id.3064*
"We also do Pro-Account trading in Commodity Segment.."
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
Attention Investors:
"Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your Stock Brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors"
"Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day......................issued in the interest of investors."
"No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
© 2013 Globe Capital Market Limited. All rights reserved
Designed, Developed and Content powered by C-MOTS Infotech (ISO 9001:2008 Certified) Privacy Policy Disclaimer Terms and Conditions